tiprankstipranks
Trending News
More News >
ACADIA Pharmaceuticals (ACAD)
NASDAQ:ACAD
US Market
Advertisement

ACADIA Pharmaceuticals (ACAD) Stock Forecast & Price Target

Compare
2,404 Followers
See the Price Targets and Ratings of:

ACAD Analyst Ratings

Moderate Buy
18Ratings
Moderate Buy
12 Buy
5 Hold
1 Sell
Based on 18 analysts giving stock ratings to
ACADIA
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

ACAD Stock 12 Month Forecast

Average Price Target

$29.88
▲(38.72% Upside)
Based on 18 Wall Street analysts offering 12 month price targets for ACADIA Pharmaceuticals in the last 3 months. The average price target is $29.88 with a high forecast of $40.00 and a low forecast of $17.00. The average price target represents a 38.72% change from the last price of $21.54.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"$13","20":"$20","27":"$27","34":"$34","41":"$41"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":40,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$40.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.88,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$29.88</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$17.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,20,27,34,41],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Mar<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.69,26.790769230769232,27.891538461538463,28.992307692307694,30.093076923076925,31.193846153846156,32.29461538461538,33.395384615384614,34.496153846153845,35.596923076923076,36.69769230769231,37.79846153846154,38.89923076923077,{"y":40,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.69,26.012307692307694,26.334615384615386,26.65692307692308,26.97923076923077,27.301538461538463,27.623846153846152,27.946153846153848,28.268461538461537,28.59076923076923,28.913076923076922,29.235384615384614,29.557692307692307,{"y":29.88,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.69,25.021538461538462,24.353076923076923,23.684615384615384,23.01615384615385,22.34769230769231,21.67923076923077,21.01076923076923,20.342307692307692,19.673846153846156,19.005384615384614,18.336923076923078,17.66846153846154,{"y":17,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":16.58,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.3,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.81,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.61,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.35,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.66,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.6,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.57,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.46,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.36,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 41,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.53,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.69,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$40.00Average Price Target$29.88Lowest Price Target$17.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on ACAD
Mizuho Securities
Mizuho Securities
$22$24
Hold
11.42%
Upside
Reiterated
10/08/25
Mizuho Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)We maintain our $24 PT and Neutral rating.
J.P. Morgan Analyst forecast on ACAD
J.P. Morgan
J.P. Morgan
$34$33
Buy
53.20%
Upside
Reiterated
09/29/25
J.P. Morgan Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)JPMorgan analyst Tessa Romero lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $34.00) while maintaining a Overweight rating.
BMO Capital Analyst forecast on ACAD
BMO Capital
BMO Capital
$28$26
Buy
20.71%
Upside
Reiterated
09/25/25
BMO Capital Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Deutsche Bank  Analyst forecast on ACAD
Deutsche Bank
Deutsche Bank
$35$29
Buy
34.63%
Upside
Reiterated
09/25/25
Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche BankAcadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank
TD Cowen Analyst forecast on ACAD
TD Cowen
TD Cowen
$39$35
Buy
62.49%
Upside
Reiterated
09/24/25
ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
Robert W. Baird Analyst forecast on ACAD
Robert W. Baird
Robert W. Baird
$31
Buy
43.92%
Upside
Reiterated
09/24/25
ACADIA Pharmaceuticals (ACAD) Receives a Buy from Robert W. BairdBaird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Leerink Partners Analyst forecast on ACAD
Leerink Partners
Leerink Partners
$32
Buy
48.56%
Upside
Reiterated
09/24/25
Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target
Stifel Nicolaus Analyst forecast on ACAD
Stifel Nicolaus
Stifel Nicolaus
Hold
Reiterated
09/24/25
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel NicolausStifel analyst Paul Matteis reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD).
Needham Analyst forecast on ACAD
Needham
Needham
$30$28
Buy
29.99%
Upside
Reiterated
09/24/25
Positive Outlook for ACADIA Pharmaceuticals Despite Setbacks: Buy Rating Justified
Morgan Stanley Analyst forecast on ACAD
Morgan Stanley
Morgan Stanley
$24
Hold
11.42%
Upside
Reiterated
09/24/25
Balanced Hold Rating for ACADIA Pharmaceuticals Amid Trial Setback and Growth PotentialWe remain EW on ACAD shares and look forward to the ACP-204 readout in 2026.
Canaccord Genuity Analyst forecast on ACAD
Canaccord Genuity
Canaccord Genuity
$32
Buy
48.56%
Upside
Reiterated
09/24/25
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
Oppenheimer
$22$21
Hold
-2.51%
Downside
Reiterated
09/24/25
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Oppenheimer
Bank of America Securities Analyst forecast on ACAD
Bank of America Securities
Bank of America Securities
$27
Hold
25.35%
Upside
Reiterated
09/24/25
Bank of America Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
UBS
$39
Buy
81.06%
Upside
Reiterated
09/23/25
UBS Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)UBS analyst Ashwani Verma reiterated a Buy rating and $39.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Citizens JMP Analyst forecast on ACAD
Citizens JMP
Citizens JMP
$38
Buy
76.42%
Upside
Reiterated
09/19/25
Citizens JMP Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $38.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Mizuho Securities Analyst forecast on ACAD
Mizuho Securities
Mizuho Securities
$22$24
Hold
11.42%
Upside
Reiterated
10/08/25
Mizuho Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)We maintain our $24 PT and Neutral rating.
J.P. Morgan Analyst forecast on ACAD
J.P. Morgan
J.P. Morgan
$34$33
Buy
53.20%
Upside
Reiterated
09/29/25
J.P. Morgan Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)JPMorgan analyst Tessa Romero lowered the price target on Acadia Pharmaceuticals (NASDAQ: ACAD) to $33.00 (from $34.00) while maintaining a Overweight rating.
BMO Capital Analyst forecast on ACAD
BMO Capital
BMO Capital
$28$26
Buy
20.71%
Upside
Reiterated
09/25/25
BMO Capital Keeps Their Buy Rating on ACADIA Pharmaceuticals (ACAD)BMO Capital analyst Evan David Seigerman reiterated an Outperform rating and $28.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Deutsche Bank  Analyst forecast on ACAD
Deutsche Bank
Deutsche Bank
$35$29
Buy
34.63%
Upside
Reiterated
09/25/25
Acadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche BankAcadia Pharmaceuticals price target lowered to $29 from $35 at Deutsche Bank
TD Cowen Analyst forecast on ACAD
TD Cowen
TD Cowen
$39$35
Buy
62.49%
Upside
Reiterated
09/24/25
ACADIA Pharmaceuticals: Growth Potential Despite Setbacks with Promising Pipeline and Core Business Expansion
Robert W. Baird Analyst forecast on ACAD
Robert W. Baird
Robert W. Baird
$31
Buy
43.92%
Upside
Reiterated
09/24/25
ACADIA Pharmaceuticals (ACAD) Receives a Buy from Robert W. BairdBaird analyst Joel Beatty reiterated an Outperform rating and $31.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Leerink Partners Analyst forecast on ACAD
Leerink Partners
Leerink Partners
$32
Buy
48.56%
Upside
Reiterated
09/24/25
Optimistic Outlook for ACADIA Pharmaceuticals Despite Recent Setback: Buy Rating and $32 Price Target
Stifel Nicolaus Analyst forecast on ACAD
Stifel Nicolaus
Stifel Nicolaus
Hold
Reiterated
09/24/25
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Stifel NicolausStifel analyst Paul Matteis reiterated a Hold rating on Acadia Pharmaceuticals (NASDAQ: ACAD).
Needham Analyst forecast on ACAD
Needham
Needham
$30$28
Buy
29.99%
Upside
Reiterated
09/24/25
Positive Outlook for ACADIA Pharmaceuticals Despite Setbacks: Buy Rating Justified
Morgan Stanley Analyst forecast on ACAD
Morgan Stanley
Morgan Stanley
$24
Hold
11.42%
Upside
Reiterated
09/24/25
Balanced Hold Rating for ACADIA Pharmaceuticals Amid Trial Setback and Growth PotentialWe remain EW on ACAD shares and look forward to the ACP-204 readout in 2026.
Canaccord Genuity Analyst forecast on ACAD
Canaccord Genuity
Canaccord Genuity
$32
Buy
48.56%
Upside
Reiterated
09/24/25
Canaccord Genuity Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)
Oppenheimer
$22$21
Hold
-2.51%
Downside
Reiterated
09/24/25
ACADIA Pharmaceuticals (ACAD) Receives a Hold from Oppenheimer
Bank of America Securities Analyst forecast on ACAD
Bank of America Securities
Bank of America Securities
$27
Hold
25.35%
Upside
Reiterated
09/24/25
Bank of America Securities Remains a Hold on ACADIA Pharmaceuticals (ACAD)BofA Securities analyst Tazeen Ahmad reiterated a Neutral rating and $27.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
UBS
$39
Buy
81.06%
Upside
Reiterated
09/23/25
UBS Sticks to Its Buy Rating for ACADIA Pharmaceuticals (ACAD)UBS analyst Ashwani Verma reiterated a Buy rating and $39.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Citizens JMP Analyst forecast on ACAD
Citizens JMP
Citizens JMP
$38
Buy
76.42%
Upside
Reiterated
09/19/25
Citizens JMP Reaffirms Their Buy Rating on ACADIA Pharmaceuticals (ACAD)Citizens JMP analyst Jason Butler reiterated a Market Outperform rating and $38.00 price target on Acadia Pharmaceuticals (NASDAQ: ACAD).
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering ACADIA Pharmaceuticals

1 Month
xxx
Success Rate
16/29 ratings generated profit
55%
Average Return
+1.29%
reiterated a xxx
rating 20 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 55.17% of your transactions generating a profit, with an average return of +1.29% per trade.
3 Months
xxx
Success Rate
7/13 ratings generated profit
54%
Average Return
+1.20%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 53.85% of your transactions generating a profit, with an average return of +1.20% per trade.
1 Year
Ritu BaralTD Cowen
Success Rate
16/28 ratings generated profit
57%
Average Return
+4.25%
reiterated a buy rating 15 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 57.14% of your transactions generating a profit, with an average return of +4.25% per trade.
2 Years
xxx
Success Rate
9/13 ratings generated profit
69%
Average Return
+15.47%
reiterated a xxx
rating 15 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 69.23% of your transactions generating a profit, with an average return of +15.47% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

ACAD Analyst Recommendation Trends

Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
15
19
16
8
12
Buy
15
24
25
23
17
Hold
8
12
13
12
13
Sell
0
1
1
2
1
Strong Sell
0
0
0
0
0
total
38
56
55
45
43
In the current month, ACAD has received 29 Buy Ratings, 13 Hold Ratings, and 1 Sell Ratings. ACAD average Analyst price target in the past 3 months is 29.88.
Each month's total comprises the sum of three months' worth of ratings.

ACAD Financial Forecast

ACAD Earnings Forecast

Next quarter’s earnings estimate for ACAD is $0.14 with a range of $0.09 to $0.22. The previous quarter’s EPS was $0.16. ACAD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ACAD has Preformed in-line its overall industry.
Next quarter’s earnings estimate for ACAD is $0.14 with a range of $0.09 to $0.22. The previous quarter’s EPS was $0.16. ACAD beat its EPS estimate 0.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year ACAD has Preformed in-line its overall industry.

ACAD Sales Forecast

Next quarter’s sales forecast for ACAD is $277.08M with a range of $272.00M to $291.06M. The previous quarter’s sales results were $264.57M. ACAD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ACAD has Preformed in-line its overall industry.
Next quarter’s sales forecast for ACAD is $277.08M with a range of $272.00M to $291.06M. The previous quarter’s sales results were $264.57M. ACAD beat its sales estimates 0.00% of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year ACAD has Preformed in-line its overall industry.

ACAD Stock Forecast FAQ

What is ACAD’s average 12-month price target, according to analysts?
Based on analyst ratings, ACADIA Pharmaceuticals’s 12-month average price target is 29.88.
    What is ACAD’s upside potential, based on the analysts’ average price target?
    ACADIA Pharmaceuticals has 38.72% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is ACAD a Buy, Sell or Hold?
          ACADIA Pharmaceuticals has a consensus rating of Moderate Buy which is based on 12 buy ratings, 5 hold ratings and 1 sell ratings.
            What is ACADIA Pharmaceuticals’s price target?
            The average price target for ACADIA Pharmaceuticals is 29.88. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $40.00 ,the lowest forecast is $17.00. The average price target represents 38.72% Increase from the current price of $21.54.
              What do analysts say about ACADIA Pharmaceuticals?
              ACADIA Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.
                How can I buy shares of ACAD?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What am I Missing?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis